UNSPSC 51111716: Rituximab

This classification denotes a monoclonal antibody with the molecular formula C6416H9874N1688O1987S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4F4X42SYQ6, more generally known as rituximab. European Medicines Agency schedules rituximab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12570MIG. The term RITUXIMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 12 no. 1 1998, list 39. Most nations schedule rituximab under HS 30021091 and SITC 54163.

As of Q4 2014, RITUXIMAB remains the US FDA Preferred Term for this commodity. Rituximab bears US NLM identifiers UMLS ID C0732355 and NCI Concept Code C1702. SMILES: CC(=O)NC1C(C(C(OC1N)CO)O)O.

UNSPSC 51111716 Rituximab is a Commodity code describing a specific pharmaceutical product — a monoclonal antibody used in treating certain cancers and autoimmune conditions — that state and local health systems, Medicaid agencies, and public hospital networks procure through bulk purchasing, pharmacy benefit management programs, and direct-to-manufacturer agreements. The code captures procurement of the drug itself rather than related services, and state and local governments buy it primarily to support treatment protocols in Medicaid programs, public health clinics, and integrated delivery systems. Issuing bodies include state health and human services departments, county health departments, and public hospital systems, though the recent opportunities block shows only one posted solicitation tied directly to this code.

Texas Health and Human Services Commission issued Request for Information (RFI) No. HHS0017013 in late March 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with a response deadline of April 3, 2026. The RFI solicits information about vendors' capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment and cost management, including experience with direct contracting for self-insured employers and government health plans, flexibility with negotiated net pricing models, and ability to implement outcomes-based agreements. No award value, budget range, or set-aside designations are identified in the RFI materials, as the state is conducting preliminary market research to inform future formal solicitations. Geographic activity is limited to the single Texas opportunity in the recent-opportunities block; the sparse posting record suggests the code sees limited recent state and local procurement activity in public notices.